References
Waldman, T., Lengauer, C., Kinzler, K. W. & Vogelstein, B. Nature 381, 713–716 (1996).
Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. Cell 74, 957–967 (1993).
Sjögren, S. et al. J. Natl Cancer Inst. 88, 173–182 (1996).
Esrig, D. et al. N. Engl. J. Med. 331, 1259–1264 (1994).
Skinner, D. G. et al. J. Urol. 145, 459–467 (1991).
Esrig, D. et al. Am. J. Pathol. 143, 1389–1397 (1993).
Pike, M. C. J. R. Stat. Soc. A 135, 201–203 (1972).
Kaplan, E. L. & Meier, P. J. Am. Stat. Assoc. 53, 457–481 (1958).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cote, R., Esrig, D., Groshen, S. et al. p53 and treatment of bladder cancer. Nature 385, 123–124 (1997). https://doi.org/10.1038/385123b0
Issue Date:
DOI: https://doi.org/10.1038/385123b0
- Springer Nature Limited
This article is cited by
-
Genomic Subtyping in Bladder Cancer
Current Urology Reports (2020)
-
YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
Oncogene (2016)
-
RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells
Cell Death & Disease (2015)
-
Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells
World Journal of Surgical Oncology (2013)
-
Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer
Surgery Today (2012)